Questcor Pharmaceuticals (QCOR +3.7%) reports significantly higher prescription growth in August...
Questcor Pharmaceuticals (QCOR +3.7%) reports significantly higher prescription growth in August for its lead product, Acthar Gel. The company says that during the period, it shipped a total of 2,190 vials of Acthar to CuraScript SD, an increase of 33% M/M. Jefferies says the prescription data was strong and that the company will likely beat the Q3 consensus revenue estimate. The firm reiterates a Buy with a $60 price target.
From other sites
at Nasdaq.com (Apr 9, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs